Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Liquidia makes and sells an inhaled medicine for a serious lung disease and earns money from selling it and licensing related technology.
Liquidia is a small drug company that sells one main product: an inhaled powder medicine called Yutrepia, used to treat pulmonary arterial hypertension, a rare and life-threatening condition where the blood vessels in the lungs tighten and force the heart to work too hard. Yutrepia is breathed in through a small handheld device, so the drug goes straight to the lungs instead of traveling through the whole body, which can mean fewer side effects. The patients here are people with this serious lung-heart disease, and the people who pay are usually insurance companies and government health programs, not the patients themselves.
The company also owns a second, quieter business: a printing-like technology platform called PRINT, which makes tiny drug particles with very precise shapes and sizes. Liquidia licenses this technology to other drugmakers and researchers who want to use it to improve their own medicines. Think of it as a company that both sells its own ice cream and rents out its special ice cream machine to other shops. The Yutrepia business is the one that matters most for revenue today, while PRINT is more of a side bet that could pay off later.
Liquidia's story has been messy and dramatic. It was founded in 2004 and spent years mostly as a technology and licensing company before betting its future on Yutrepia. That bet led to a long, bitter legal fight with United Therapeutics, a much bigger rival that sells a similar inhaled drug called Tyvaso. A court battle over patents dragged on for years, and the two sides even struck a deal in 2024 that would have let Liquidia sell a version of Tyvaso while paying royalties, though the situation kept shifting. The company is still tiny, unprofitable, and burning cash as it tries to ramp up Yutrepia sales, which means its stock swings wildly on legal and regulatory news rather than steady profits. It doesn't pay dividends and doesn't buy back shares; any extra money goes back into launching its drug and fighting its legal battles.
Saved answer · last researched 11 Oct 2026